Ultragenyx Pharma (RARE) Misses Q2 EPS by 2c

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.46), $0.02 worse than the analyst estimate of ($1.44).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Goldman Sachs reports global fund inflows for week of July 8
• Apollo agrees to buy EasyJet Plc. (EZJ:LN) (ESYJY); Bernstein SocGen shares investment implications